Administration of the DMRIE/DOPE DNA-liposome complex at up to 1,000-fold higher concentrations than previously tolerated produced no detectable toxicities in mice and pigs.
Is the novel cationic lipid formulation DMRIE/DOPE safe and well-tolerated in vivo in mice and pigs?
The DMRIE/DOPE cationic lipid formulation is well-tolerated in preclinical models, potentially enabling higher-dose nonviral gene therapy.
Among the potential nonviral vectors for human gene therapy are DNA–liposome complexes. In a recent clinical study, this delivery system has been utilized. In this report, a novel cationic lipid, dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium (DMRIE), has been substituted into the DNA–liposome complex with dioleoyl phosphatidylethanolamine (DOPE), which both improves transfection efficiencies and allows increased doses of DNA to be delivered in vivo. The safety and toxicity of this DNA–liposome complex has been evaluated in two species, mice and pigs. The efficacy of DMRIE/DOPE in inducing an antitumor response in mice after transfer of a foreign MHC has been confirmed. No abnormalities were detected after administration of up to 1,000-fold higher concentrations of DNA and lipid than could be tolerated in vivo previously. Examination of serum biochemical enzymes, pathologic examination of tissue, and analysis of cardiac function in mice and pigs revealed no toxicities related to this treatment. This improved cationic lipid formulation is well-tolerated in vivo and could therefore allow higher dose administration and potentially greater efficiency of gene transfer for gene therapy. Although several viral vectors have been widely applied to the treatment of human disease, the development of nonviral vectors is still in their infancy. In this report, a novel cationic lipid, DMRIE/DOPE, has been incorporated into the DNA–liposome formulation that improves transfection efficiencies and allows up to 1,000-fold higher concentrations of DNA to be administered in vivo. In this paper, the safety and toxicity of this formulation is described in two species, mice and pigs, suggesting that it may prove useful for human gene therapy.
San et al. (Wed,) reported a other. DMRIE/DOPE DNA-liposome complex was evaluated on Safety and toxicity (serum biochemical enzymes, pathologic examination of tissue, and cardiac function). Administration of the DMRIE/DOPE DNA-liposome complex at up to 1,000-fold higher concentrations than previously tolerated produced no detectable toxicities in mice and pigs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: